KOBCELYX Trademark

Trademark Overview

On Monday, May 9, 2022, a trademark application was filed for KOBCELYX with the United States Patent and Trademark Office. The USPTO has given the KOBCELYX trademark a serial number of 97400939. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Wednesday, August 28, 2024. This trademark is owned by Regeneron Pharmaceuticals, Inc.. The KOBCELYX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral diseases and disorders, and for the treatment of pain
kobcelyx

General Information

Serial Number97400939
Word MarkKOBCELYX
Filing DateMonday, May 9, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateWednesday, August 28, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 24, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral diseases and disorders, and for the treatment of pain

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, May 13, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameRegeneron Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591
Party NameRegeneron Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591

Trademark Events

Event DateEvent Description
Thursday, May 12, 2022NEW APPLICATION ENTERED
Friday, May 13, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 14, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 14, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 14, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, December 19, 2022ASSIGNED TO EXAMINER
Thursday, December 22, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 4, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 24, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 24, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 21, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 23, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 23, 2023SOU EXTENSION 1 FILED
Wednesday, August 23, 2023SOU EXTENSION 1 GRANTED
Friday, August 25, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 21, 2024SOU EXTENSION 2 FILED
Monday, April 22, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, April 22, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Thursday, May 9, 2024TEAS PETITION TO REVIVE RECEIVED
Thursday, May 9, 2024PETITION TO REVIVE-GRANTED
Thursday, May 9, 2024NOTICE OF REVIVAL - E-MAILED
Thursday, May 9, 2024SOU EXTENSION RECEIVED WITH TEAS PETITION
Thursday, May 9, 2024TEAS PETITION TO REVIVE RECEIVED
Tuesday, July 23, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, July 24, 2024SOU EXTENSION 2 GRANTED
Wednesday, July 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 28, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, August 28, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 28, 2024SOU EXTENSION 3 FILED
Wednesday, August 28, 2024SOU EXTENSION 3 GRANTED

Related Keywords

kobcelyx treatment nephrological hepatological autoimmune dermatological tissue allergic infectious genetic disorders